Base de dados : MEDLINE
Pesquisa : D27.505.519.389.745.085 [Categoria DeCS]
Referências encontradas : 30525 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3053 ir para página                         

  1 / 30525 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29408872
[Au] Autor:Gupta N; Srivastava N; Bhagyawant SS
[Ad] Endereço:School of Studies in Biotechnology, Jiwaji University, Gwalior, India.
[Ti] Título:Vicilin-A major storage protein of mungbean exhibits antioxidative potential, antiproliferative effects and ACE inhibitory activity.
[So] Source:PLoS One;13(2):e0191265, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Enzymatic hydrolysates of different food proteins demonstrate health benefits. Search for diet related food protein hydrolysates is therefore of interest within the scope of functional foods. Mungbean is one of the popular foods in India because of rich protein source. In this study, mungbean vicilin protein (MBVP) was enzymatically hydrolysed by alcalase and trypsin under optimal conditions. We have studied the antioxidant, antiproliferative and angiotensin-converting enzyme (ACE) inhibitory activities of mungbean vicilin protein hydrolysate (MBVPH) vis-a-vis alcalase-generated mungbean vicilin protein hydrolysate (AMBVPH) and trypsin-generated mungbean vicilin protein hydrolysate (TMBVPH). The results showed that MBVPH exhibited higher antioxidant potential, ACE inhibitory and antiproliferative activities than MBVP. The alcalase treated hydrolysate displayed highest ACE inhibitory activity with IC50 value of 0.32 mg protein/ml. The MBVP showed significant antiproliferative activity against both MCF-7 and MDA-MB-231 breast cancer cells at the doses between 0.2-1.0 mg/ml. The data suggested that MBVPH can be utilized as physiologically active functional foods with sufficient antihypertensive activity. The results indicate that mungbean can be utilized as a rich resource of functional foods.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/farmacologia
Antioxidantes/farmacologia
Proliferação Celular/efeitos dos fármacos
Fabaceae/metabolismo
Proteínas de Plantas/metabolismo
[Mh] Termos MeSH secundário: Animais
Depuradores de Radicais Livres/metabolismo
Seres Humanos
Coelhos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Antioxidants); 0 (Free Radical Scavengers); 0 (Plant Proteins)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191265


  2 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28471687
[Au] Autor:Certíková Chábová V; Cervenka L
[Ad] Endereço:Department of Nephrology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. luce@ikem.cz.
[Ti] Título:The dilemma of dual renin-angiotensin system blockade in chronic kidney disease: why beneficial in animal experiments but not in the clinic?
[So] Source:Physiol Res;66(2):181-192, 2017 May 04.
[Is] ISSN:1802-9973
[Cp] País de publicação:Czech Republic
[La] Idioma:eng
[Ab] Resumo:Drugs interfering with the renin-angiotensin-aldosterone system (RAAS) improved the prognosis in patients with hypertension, heart failure, diabetes and chronic kidney disease. However, combining different drugs brought no further benefit while increasing the risk of hyperkalemia, hypotension and acute renal failure. This was so with combining angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptors type 1 antagonists (ARB). Dissimilarly, in animal disease models this dual therapy proved clearly superior to single drug treatment and became the optimal standard regime for comparison with other treatments. This review analyzes the causes of the discrepancy of effects of the dual therapy between animal experiments versus clinical studies, and is focused on the outcomes in chronic kidney disease. Discussed is the role of species differences in RAAS, of the variability of the disease features in humans versus relative stability in animals, of the genetic uniformity in the animals but not in humans, and of the biased publication habits of experimental versus clinical studies. We attempt to understand the causes and reconcile the discordant findings and suggest to what extent dual RAAS inhibition should be continued in animal experiments and why its application in the clinics should be limited to strictly selected groups of patients.
[Mh] Termos MeSH primário: Bloqueadores do Receptor Tipo 1 de Angiotensina II/administração & dosagem
Inibidores da Enzima Conversora de Angiotensina/administração & dosagem
Modelos Animais de Doenças
Insuficiência Renal Crônica/tratamento farmacológico
Insuficiência Renal Crônica/imunologia
Sistema Renina-Angiotensina/efeitos dos fármacos
Sistema Renina-Angiotensina/imunologia
[Mh] Termos MeSH secundário: Lesão Renal Aguda/induzido quimicamente
Lesão Renal Aguda/imunologia
Lesão Renal Aguda/prevenção & controle
Inibidores da Enzima Conversora de Angiotensina/efeitos adversos
Animais
Medicina Baseada em Evidências
Seres Humanos
Hiperpotassemia/induzido quimicamente
Hiperpotassemia/imunologia
Hiperpotassemia/prevenção & controle
Hipertensão/induzido quimicamente
Hipertensão/imunologia
Hipertensão/prevenção & controle
Especificidade da Espécie
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Angiotensin II Type 1 Receptor Blockers); 0 (Angiotensin-Converting Enzyme Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  3 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773450
[Au] Autor:Kovarik JJ; Kopecky C; Antlanger M; Domenig O; Kaltenecker CC; Werzowa J; Hecking M; Mahr S; Grömmer M; Wallner C; Aumayr K; Kain R; Zuckermann A; Poglitsch M; Säemann MD
[Ad] Endereço:Department of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
[Ti] Título:Effects of angiotensin-converting-enzyme inhibitor therapy on the regulation of the plasma and cardiac tissue renin-angiotensin system in heart transplant patients.
[So] Source:J Heart Lung Transplant;36(3):355-365, 2017 Mar.
[Is] ISSN:1557-3117
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors (ACEis) are beneficial in patients with heart failure, yet their role after heart transplantation (HTx) remains ambiguous. Particularly, the effects of ACEis on plasma and cardiac metabolites of the "classical" and "alternative" renin-angiotensin system (RAS) in HTx patients are unknown. METHODS: This cross-sectional study used a novel mass spectrometry-based approach to analyze plasma and tissue RAS regulation in homogenates of heart biopsy specimens from 10 stable HTx patients without RAS blockade and in 15 patients with ACEi therapy. Angiotensin (Ang) levels in plasma and Ang formation rates in biopsy tissue homogenates were measured. RESULTS: Plasma Ang II formation is exclusively ACE dependent, whereas cardiac Ang II formation is primarily chymase dependent in HTx patients. ACEi therapy substantially increased plasma Ang-(1-7), the key effector of the alternative RAS, leaving plasma Ang II largely intact. Importantly, neprilysin and prolyl-carboxypeptidase but not angiotensin converting enzyme 2 are essential for cardiac tissue Ang-(1-7) formation. CONCLUSION: ACE is the key enzyme for the generation of plasma Ang II, whereas chymase is responsible for cardiac tissue production of Ang II. Furthermore, our findings reveal that neprilysin and prolyl-carboxypeptidase are the essential cardiac enzymes for the alternative RAS after HTx. These novel insights into the versatile regulation of the RAS in HTx patients might affect future therapeutic avenues, such as chymase and neprilysin inhibition, beyond classical Ang II blockade.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/administração & dosagem
Rejeição de Enxerto/prevenção & controle
Insuficiência Cardíaca/sangue
Transplante de Coração/métodos
Sistema Renina-Angiotensina/efeitos dos fármacos
[Mh] Termos MeSH secundário: Idoso
Áustria
Biópsia por Agulha
Estudos Transversais
Ecocardiografia
Feminino
Seguimentos
Sobrevivência de Enxerto
Insuficiência Cardíaca/diagnóstico por imagem
Insuficiência Cardíaca/cirurgia
Transplante de Coração/efeitos adversos
Seres Humanos
Imuno-Histoquímica
Masculino
Meia-Idade
Valores de Referência
Medição de Risco
Papel (Figurativo)
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29185789
[Au] Autor:Mou Y; Zhang Y; Guo C; Zhao J; Zhang Z; Zhou X; Dong J; Liao L
[Ad] Endereço:1 Division of Cardiology, Department of Internal Medicine, Shandong Provincial Hospital Affiliated to Shandong University , Jinan, China .
[Ti] Título:Integrated Treatment of Prostaglandin E1 and Angiotensin-Converting Enzyme Inhibitor in Diabetic Kidney Disease Rats: Possible Role of Antiapoptosis in Renal Tubular Epithelial Cells.
[So] Source:DNA Cell Biol;37(2):133-141, 2018 Feb.
[Is] ISSN:1557-7430
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:To investigate the therapeutic mechanisms underlying prostaglandin E1 (PGE1) and angiotensin-converting enzyme inhibitor (ACEI) on reducing urinary protein in diabetic kidney disease (DKD). DKD rats were established and randomly divided into four groups: PGE1 (10 µg/kg/day) (P group), ACEI (10 mg/kg/day) (A group), combination of PGE1 with ACEI treatment (P + A group), and saline treatment group (DKD group). Untreated rats were used as normal control (N group). Urinary albumin, endothelin-1 (ET-1), angiotensin II (AngII), TUNEL assay, Masson's trichrome staining, and immunohistochemistry staining for CD68 were evaluated in all groups. Ten days after treatment, urinary albumin was significantly decreased in the P and P + A groups (p < 0.01 vs. the DKD group). At the end of 8 weeks, the albumin was still significantly reduced in the P + A group (p < 0.05 vs. the A group). ET-1 and AngII were also significantly decreased in three treatment groups (p < 0.01 vs. the DKD group), especially in the P + A group. Few cells underwent apoptosis in glomerular regions in DKD rats, while amounts of apoptotic cells were seen in tubules regions. Further, apoptosis and the areas of fibrosis in tubulointerstitial were both decreased most in the P + A group compared with the DKD group. Apoptosis of renal tubular epithelial cells may participate in the development and progression of DKD in rats. Combination of PGE1 with AGEI remarkably protects renal function compared with PGE1 or ACEI monotherapy. The potential therapeutic mechanisms of PGE1 and AGEI might be via multiple targets and, at least in part, through inhibiting the apoptosis of renal tubular epithelial cells.
[Mh] Termos MeSH primário: Alprostadil/farmacologia
Inibidores da Enzima Conversora de Angiotensina/farmacologia
Diabetes Mellitus Experimental/complicações
Nefropatias Diabéticas/tratamento farmacológico
Nefrite Intersticial/tratamento farmacológico
[Mh] Termos MeSH secundário: Angiotensina II/sangue
Animais
Apoptose/efeitos dos fármacos
Diabetes Mellitus Experimental/sangue
Nefropatias Diabéticas/sangue
Nefropatias Diabéticas/etiologia
Avaliação Pré-Clínica de Medicamentos
Endotelina-1/sangue
Células Epiteliais/efeitos dos fármacos
Túbulos Renais/efeitos dos fármacos
Túbulos Renais/patologia
Macrófagos/imunologia
Masculino
Nefrite Intersticial/sangue
Nefrite Intersticial/etiologia
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Endothelin-1); 11128-99-7 (Angiotensin II); F5TD010360 (Alprostadil)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1089/dna.2017.3690


  5 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28456777
[Au] Autor:Deska P; Nowicki M
[Ad] Endereço:Department of Internal Medicine District Hospital, Klobuck, Poland.
[Ti] Título:Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.
[So] Source:J Physiol Pharmacol;68(1):133-138, 2017 Feb.
[Is] ISSN:1899-1505
[Cp] País de publicação:Poland
[La] Idioma:eng
[Ab] Resumo:Intensive physical exercise may facilitate potassium release from skeletal muscles that may result in hyperkalemia. Commonly used drugs including angiotensin converting enzyme inhibitors (ACEI) and statins increase a risk of hyperkalemia. It is not known whether the effect of these drugs on serum potassium during physical exercise is additive. The study compared the effect of physical exercise on the changes of serum potassium in hypertensive patients receiving ACEI alone or in combination with statin. Eighteen patients with arterial hypertension with normal renal function were included in a prospective placebo-controlled cross-over study. The patients underwent 3 exercise tests on a bicycle ergometer with 55 - 60% of maximum oxygen consumption each lasting 30 minutes, i.e. after being treated with ACEI alone for six months, and then in a random order after the administration of ACEI with statin or ACEI with placebo each time for eight weeks separated by 2-week wash-out. Serum potassium was measured with atomic emission flame spectrometry before and after 15 and 30 minutes exercise and after 30-minute recovery. During the exercise serum potassium concentration increased moderately but significantly during all exercise tests. Mean serum potassium during exercise remained within the normal range. There were no differences in the exercise-induced changes of serum potassium during the exercise tests performed after ACEI combined with statin or with placebo. Addition of statin to ACEI does not increase the risk of hyperkalemia in hypertensive patients with preserved renal function during physical exercise with intensity typical for routine daily activities.
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina/farmacologia
Exercício/fisiologia
Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia
Hipertensão/sangue
Potássio/sangue
Ramipril/farmacologia
Sinvastatina/farmacologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Estudos Cross-Over
Quimioterapia Combinada
Teste de Esforço
Feminino
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hipertensão/tratamento farmacológico
Hipertensão/urina
Masculino
Meia-Idade
Potássio/urina
Ramipril/uso terapêutico
Sinvastatina/uso terapêutico
Método Simples-Cego
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); AGG2FN16EV (Simvastatin); L35JN3I7SJ (Ramipril); RWP5GA015D (Potassium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  6 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419271
[Au] Autor:Flynn JT
[Ad] Endereço:University of Washington School of Medicine, Seattle, WA joseph.flynn@seattlechildrens.org
[Ti] Título:ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
[So] Source:N Engl J Med;378(6):580, 2018 02 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina
Inibidores de Hidroximetilglutaril-CoA Redutases
[Mh] Termos MeSH secundário: Diabetes Mellitus Tipo 1
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1715763


  7 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419270
[Au] Autor:Mei ZB; Xiao Y
[Ad] Endereço:Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China herrmayor@126.com
[Ti] Título:ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
[So] Source:N Engl J Med;378(6):579, 2018 02 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina
Inibidores de Hidroximetilglutaril-CoA Redutases
[Mh] Termos MeSH secundário: Diabetes Mellitus Tipo 1
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1715763


  8 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419269
[Au] Autor:Jonnalagadda VG; Metety VK; Choudhary
[Ad] Endereço:National Institute of Pharmaceutical Education and Research, Guwahati, India gopalvenu63@gmail.com
[Ti] Título:ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
[So] Source:N Engl J Med;378(6):579, 2018 02 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina
Inibidores de Hidroximetilglutaril-CoA Redutases
[Mh] Termos MeSH secundário: Diabetes Mellitus Tipo 1
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1715763


  9 / 30525 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29414269
[Au] Autor:Dunger DB; Marcovecchio ML; Deanfield J
[Ad] Endereço:University of Cambridge, Cambridge, United Kingdom dbd25@cam.ac.uk
[Ti] Título:ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
[So] Source:N Engl J Med;378(6):580-581, 2018 02 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores da Enzima Conversora de Angiotensina
Inibidores de Hidroximetilglutaril-CoA Redutases
[Mh] Termos MeSH secundário: Diabetes Mellitus Tipo 1
Seres Humanos
[Pt] Tipo de publicação:LETTER; COMMENT
[Nm] Nome de substância:
0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180208
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMc1715763


  10 / 30525 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381974
[Au] Autor:Zhang J; Liu X; Liu X; Yin X; Wang Y; Lu X; Yang X
[Ad] Endereço:Cardiac Center, Beijing Chaoyang Hospital affiliated to Capital Medical University, Beijing, China.
[Ti] Título:Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation: A real-world experience.
[So] Source:Medicine (Baltimore);96(47):e8762, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We assessed the thromboembolic risks of atrial fibrillation (AF) patients who had undergone radiofrequency ablation (RFA) using the CHADS2-VASc risk scoring system and further investigated the patterns of warfarin use for thromboprophylaxis according to patient thromboembolic risk scores.In this study, we analyzed the stroke risks of patients who had undergone RFA for AF at our hospital between March 2014 and June 2016 using the CHADS2, CHADS2-VASc, and Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (> 65 years) (HAS-BLED) scoring systems. We retrieved medications, co-morbidities, and initial warfarin dosage data. The primary outcome was the percentage of patients initiated with warfarin therapy for stroke prophylaxis in AF who had a CHADS2-VASc score of 0.Totally, 309 patients were initiated with warfarin therapy for stroke prophylaxis in AF post-RFA. The baseline warfarin dosage was 2.76 ±â€Š0.61 mg. The baseline CHADS2-VASC score was 2.93 ±â€Š1.96 and 40 (12.95%) had a CHADS2-VASC score of 0, 42 (13.6%) had a CHADS2-VASCscore of 1, and 227 (73.5%) had a CHADS2-VASC score ≥2. The baseline CHADS2 score was 2.17 ±â€Š1.55 and 48 (15.5%) had a CHADS2 score of 0, 68 (22.0%) had a CHADS2 score of 1, and 193 (62.5%) had a CHADS2 score ≥2. The baseline HAS-BLED score was 1.25 ±â€Š0.91 and 69 (22.3%) had a HAS-BLED score of 0, 121 (39.2%) had a HAS-BLED score of 1, and 119 (38.5%) had a HAS-BLED score ≥2. Patients aged <65 years or 65 years, male and female patients, patients with or without hypertension, coronary heart disease, or diabetes mellitus, and patients with or without previous stroke/transient ischemic attack differed significantly in stroke risks by CHADS2-VASC, CHADS2, and HAS-BLED scores for stroke risks. Patients with different baseline international normalized ratio differed significantly in CHADS2-VASC scores. Furthermore, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and statins were of statistical significance for stroke risks.The majority of AF patients post-RFAs was of high stroke risk and received warfarin thromboprophylaxis in accordance with national guidelines. Our findings suggest that low and intermediate stroke risk patients should be evaluated for stroke risks and risk factors so that tailored warfarin thromboprophylaxis therapy can be given and inappropriate use of warfarin in AF patients can be avoided.
[Mh] Termos MeSH primário: Anticoagulantes/administração & dosagem
Fibrilação Atrial/complicações
Medição de Risco/métodos
Acidente Vascular Cerebral/etiologia
Varfarina/administração & dosagem
[Mh] Termos MeSH secundário: Idoso
Antagonistas de Receptores de Angiotensina/uso terapêutico
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico
Fibrilação Atrial/cirurgia
Ablação por Cateter/métodos
Feminino
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Coeficiente Internacional Normatizado
Masculino
Estudos Retrospectivos
Fatores de Risco
Acidente Vascular Cerebral/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiotensin Receptor Antagonists); 0 (Angiotensin-Converting Enzyme Inhibitors); 0 (Anticoagulants); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 5Q7ZVV76EI (Warfarin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008762



página 1 de 3053 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde